Overview
Product name | Recombinant Human LILRB3/ILT-5/CD85a Protein |
---|
Catalog No. | RP01436 |
---|
Description | Recombinant Human LILRB3/ILT-5/CD85a Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly24-Glu443) of human LILRB3/CD85a/ILT5 (Accession #XP_016885786.1) fused with a 6×His,Avi tag at the C-terminus. |
---|
Purity | > 95% by SDS-PAGE. |
---|
Endotoxin | <1EU/μg |
---|
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
---|
Species | Human |
---|
Calculated MW | 48.72 kDa |
---|
Background
Leukocyte immunoglobulin-like receptor subfamily B member 3, also known as Leukocyte immunoglobulin-like receptor 3, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9, CD85 antigen-like family member A, CD85a and LILRB3, is a single-pass type I membrane protein that belongs to the leukocyte receptor cluster (LRC) present on 19q13.4. LILRB3 / CD85a contains four Ig-like C2-type (immunoglobulin-like) domains. LILRB3 / CD85a contains three copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in the modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases. LILRB3 / CD85a is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found.
Product information
Synonym | LILRB3; CD85A; HL9; ILT-5; ILT5; LILRA6; LIR-3; LIR3; PIR-B; PIRB |
---|
Expression Host | HEK293 cells |
---|
Tag | C-His&Avi |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.